A · NYQ · Healthcare
Agilent Technologies, Inc.
Also onShortfallConsensus DriftCrosscheck
Implied value per share
USD 66.27
Market price
USD 171.99
Implied upside
-61.5%
10-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case · Price 2026-11-02 · Accounts to 2025-10-31
Current EV/EBITDA of 28.3x sits outside a defensible 3-20x band, so the exit multiple is capped at 20.0x. A multiple that far out usually means EBITDA is the wrong denominator for this business.
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (USD). Outflows negative.
| Line | FY26 | FY27 | FY28 | FY29 | FY30 | FY31 | FY32 | FY33 | FY34 | FY35 | CAGR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | USD 7.5bn | USD 8.0bn | USD 8.5bn | USD 8.9bn | USD 9.4bn | USD 9.8bn | USD 10.2bn | USD 10.5bn | USD 10.8bn | USD 11.1bn | +4.5% |
| EBIT | USD 1.6bn | USD 1.7bn | USD 1.9bn | USD 2.0bn | USD 2.0bn | USD 2.1bn | USD 2.2bn | USD 2.3bn | USD 2.4bn | USD 2.4bn | +4.5% |
| NOPAT | USD 1.4bn | USD 1.5bn | USD 1.6bn | USD 1.7bn | USD 1.8bn | USD 1.9bn | USD 2.0bn | USD 2.0bn | USD 2.1bn | USD 2.1bn | +4.5% |
| Add depreciation & amortisation | USD 312.9m | USD 333.0m | USD 352.7m | USD 371.9m | USD 390.3m | USD 407.7m | USD 423.9m | USD 438.7m | USD 451.8m | USD 463.1m | +4.5% |
| Less capital expenditure | USD -380.1m | USD -427.2m | USD -476.4m | USD -527.6m | USD -580.2m | USD -633.8m | USD -687.7m | USD -741.4m | USD -794.2m | USD -845.5m | +9.3% |
| Capex, % of revenue | 5.1% | 5.4% | 5.6% | 5.9% | 6.2% | 6.5% | 6.8% | 7.1% | 7.3% | 7.6% | - |
| Less increase in working capital | USD -152.0m | USD -132.6m | USD -130.3m | USD -126.6m | USD -121.5m | USD -114.9m | USD -106.8m | USD -97.4m | USD -86.6m | USD -74.5m | -7.6% |
| Free cashflow to firm | USD 1.2bn | USD 1.3bn | USD 1.4bn | USD 1.4bn | USD 1.5bn | USD 1.5bn | USD 1.6bn | USD 1.6bn | USD 1.7bn | USD 1.7bn | +3.6% |
| Discount factor | 0.9558 | 0.8732 | 0.7977 | 0.7287 | 0.6657 | 0.6082 | 0.5556 | 0.5076 | 0.4637 | 0.4236 | - |
| Present value | USD 1.2bn | USD 1.1bn | USD 1.1bn | USD 1.0bn | USD 989.0m | USD 934.3m | USD 878.4m | USD 822.0m | USD 765.5m | USD 709.5m | - |
| Present Value Of The Forecast | USD 9.5bn | ||||||||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 4.89% | US 10-year Treasury (^TNX), 2026-11-02 |
| Equity risk premium | 4.23% | Damodaran, January 2026 |
| Beta | 1.159 | Reported 1.237, pulled toward 1.0 (Blume) |
| Cost of equity | 9.80% | Risk-free + beta x equity risk premium |
| Cost of debt | 5.29% | Risk-free + 40bp, the spread for a AAA rating at 13.2x interest cover. Book interest / average debt was lower, at 3.3%. |
| Market capitalisation | USD 48.5bn | 93.5% of capital |
| Total debt | USD 3.4bn | 6.5% of capital, book value as a proxy |
| Tax rate | 12.2% | Effective, capped at statutory |
| WACC | 9.46% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
53% of EV
- Forecast FCFF, final year
- USD 1.7bn
- Capex at depreciation, working capital in reinvestment
- USD 2.1bn
- Less reinvestment at g/ROIC (17.9% of NOPAT)
- USD -382.4m
- Capitalised
- USD 1.7bn
- ROIC (reported)
- 13.9%
- Terminal value, undiscounted
- USD 25.8bn
- Terminal value, discounted
- USD 10.9bn
- Enterprise value
- USD 20.5bn
- Less net debt
- USD 1.6bn
- Equity value
- USD 18.9bn
Exit at 20.0x EBITDA
72% of EV
- Terminal value, undiscounted
- USD 57.8bn
- Terminal value, discounted
- USD 24.5bn
- Enterprise value
- USD 34.0bn
- Less net debt
- USD 1.6bn
- Equity value
- USD 32.5bn
Spread between methods: 53%.
Sensitivity
Value per share (USD) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 7.46% | 89.82 | 92.10 | 94.96 | 98.59 | 103.31 |
| 8.46% | 75.82 | 76.87 | 78.20 | 79.88 | 82.01 |
| 9.46% | 65.37 | 65.75 | 66.27 | 66.95 | 67.84 |
| 10.46% | 57.27 | 57.28 | 57.34 | 57.49 | 57.74 |
| 11.46% | 50.82 | 50.61 | 50.42 | 50.27 | 50.17 |
Outlined: this model. Green text: above today's price of 171.99. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Actual | Model | Implied | Gap |
|---|---|---|---|---|
| Revenue growth, a year | 0.5% | 4.8% | 17.0% | |
| EBIT margin | 23.6% | 21.9% | 52.5% | |
| Discount rate | - | 9.5% | 5.3% |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.